Healthcare company MSD Ireland has appointed five new site leads across its five Irish sites. MSD employs more than 3,000 people in Ireland.
The new site leads are: Matt Maher in Ballydine, Co Tipperary; Donal Kelleher in Brinny, Co Cork; Martha Bomar in Dunboyne, Co Meath; Kacey Fetcho-Phillips in Co Dublin; and Eva Gallagher in Co Carlow.
MSD’s Irish sites manufacture approximately half of MSD’s top 20 healthcare products.
The company has invested over $6bn in its Irish operations and our annual turnover ranks MSD as one of Ireland’s top 20 companies.
The new site leads will champion the company’s manufacturing and R&D plants across the country, continuously looking to grow and deepen MSD’s presence in Ireland and contribution to the local communities it operates in.
Eva Gallagher said: “MSD Carlow plays an integral role in MSD’s worldwide operations, delivering important vaccines and treatments for individuals and patients internationally. I take immense pride in leading our MSD Carlow site, with its cutting-edge facilities and unwaveringly dedicated team, all working with the common goal of positively impacting countless lives globally.”
MSD Carlow is MSD’s largest filling site for the launch and commercial supply of vaccines, biologics and small molecule drug products, playing a vital role in connecting MSD’s innovative product portfolio with people and patients all over the world.
Eva Gallagher has been part of the MSD team since 2009. She has held a wide range of roles in technical operations, manufacturing, quality control, analytical development and commercialisation all across the global MSD network.
Eva previously led MSD’s Dunboyne site in Co Meath, where the research and manufacturing teams collaborate to accelerate the time it takes to bring a medicine to market.
Martha Bomar, site lead in Co Meath, said: “MSD Dunboyne brings together research and development and manufacturing within one site. The co-localisation enables innovation and scientific excellence.”
Originally from the US and with post-doctoral specialisation in Biochemistry, Martha has experience in technical, quality and operations roles across multiple MSD manufacturing sites.
MSD Dunboyne is MSD’s first Biologics Drug Substance Single Use Commercialisation Site, featuring co-localisation of both R&D and manufacturing facilities.
Kacey Fetcho-Phillips brings 20 years of pharma experience to her role as new site lead for MSD Biotech, Co Dublin, the company’s global immuno-oncology hub. She has worked in Ireland, Italy, and across the United States.
Kacey said: “MSD Biotech Dublin is a newly opened commercial biomanufacturing facility, delivering breakthrough biologic and immuno-oncology medicine. We build on the 50-year legacy of MSD Ireland by leveraging the latest in technology, digital, and innovation to better address the global health burden of challenging diseases.”
Matt Maher, site lead for MSD Ballydine, Co Tipperary, has a background in chemical engineering and microbiology. He has been part of the MSD Ireland team for almost 22 years, holding senior leadership positions.
Matt said: “I have always felt at one with our company’s commitment to making a difference for patients, for communities and for the future. I’m honoured to now be leading the MSD Ballydine site.”
Donal Kelleher, site lead for MSD Brinny, Co Cork, has a background in chemical engineering and project management. He has been part of the MSD Brinny site since 2003, working his way up to senior management positions in engineering, manufacturing operations and quality.
MSD Brinny recently celebrated the site’s 40th anniversary. The site boasts a successful legacy of developing and commercially supplying biotech products, including some of MSD’s most successful treatments for Oncology, Hepatitis C, and Rheumatoid Arthritis, as well as developing innovative novel vaccines and testing of immuno-oncology medicines.
Donal Kelleher said: “In my 20 years with MSD, I have been fortunate to have experienced many elements of our operations, our community, and our people and have seen first-hand many examples of our site’s exceptional levels of innovation, passion and dynamism. I’m excited to see what the future will hold for the next 40 years.”